This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MedCath Stockholders Approve Proposals To Sell Substantially All The Company's Assets; Shareholder Distribution Also Approved

CHARLOTTE, N.C., Sept. 22, 2011 /PRNewswire/ -- MedCath Corporation (Nasdaq: MDTH) announced that the company's stockholders today approved the proposals contained in a proxy statement filed with the Securities and Exchange Commission on August 17, 2011, authorizing the sale of substantially all of the remaining assets of MedCath and the dissolution of the company.

MedCath also announced today that its Board of Directors approved a cash distribution equal to $6.85 per share, which will be paid October 13, 2011 to stockholders of record on October 6, 2011.  The amount of the distribution is consistent with the amount of the anticipated initial distribution described in the proxy statement dated August 17, 2011.

MedCath announced in March 2010 it had formed a Strategic Options Committee to consider the sale either of the entire company or its assets. Since that time, the company has announced 10 transactions.

About MedCath

MedCath Corporation, headquartered in Charlotte, N.C., is a health care provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns an interest in and operates four hospitals with a total of 366 licensed beds, located in Arizona, California, Louisiana and Texas.  This press release contains a forward-looking statement relating to the payment of a cash distribution to stockholders. The payment of this distribution is subject to various risks, including those described in MedCath's Annual Report on Form 10-K, as amended, and its subsequent filings with the Securities and Exchange Commission.  Actual results could differ materially from those projected in this forward-looking statement. MedCath assumes no obligation to update statements contained in this press release.

SOURCE MedCath Corporation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs